Health Care • Biotechnology: Pharmaceutical Preparations
$8.00 ▼ -1.20
(-13.04%)
MKT CAP: $18.3M • VOL: 97.0K
52W L $3 52W H $34
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
AKTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $367.9K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$17.3M | -$21.6M | -$16.8M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$17.3M | -$19.8M | -$10.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$10.6M | -$12.6M | -$16.4M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$10.6M | -$12.6M | -$16.4M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.2M | $0 | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $28.3M | $22.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AKTX.